AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2007 | 6.69 Million USD | 21.72% |
| 2006 | 5.49 Million USD | 43.0% |
| 2005 | 3.84 Million USD | 15.11% |
| 2004 | 3.34 Million USD | 2.33% |
| 2003 | 3.26 Million USD | -65.25% |
| 2002 | 9.39 Million USD | -40.37% |
| 2001 | 15.75 Million USD | 26.01% |
| 2000 | 12.5 Million USD | 76.1% |
| 1999 | 7.1 Million USD | 10.94% |
| 1998 | 6.4 Million USD | 28.0% |
| 1997 | 5 Million USD | 163.16% |
| 1996 | 1.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2008 Q2 | 1.88 Million USD | -4.51% |
| 2008 Q1 | 1.97 Million USD | 11.22% |
| 2008 Q3 | 1.87 Million USD | -0.44% |
| 2007 FY | 6.69 Million USD | 21.72% |
| 2007 Q1 | 1.33 Million USD | -5.67% |
| 2007 Q2 | 1.6 Million USD | 20.21% |
| 2007 Q3 | 1.97 Million USD | 22.92% |
| 2007 Q4 | 1.77 Million USD | -10.04% |
| 2006 Q1 | 1.36 Million USD | -2.82% |
| 2006 Q3 | 1.4 Million USD | 6.55% |
| 2006 FY | 5.49 Million USD | 43.0% |
| 2006 Q4 | 1.41 Million USD | 0.92% |
| 2006 Q2 | 1.31 Million USD | -3.24% |
| 2005 Q3 | 629.14 Thousand USD | -51.31% |
| 2005 Q2 | 1.29 Million USD | 146.99% |
| 2005 FY | 3.84 Million USD | 15.11% |
| 2005 Q1 | 523.1 Thousand USD | -33.19% |
| 2005 Q4 | 1.4 Million USD | 122.66% |
| 2004 Q1 | 996.93 Thousand USD | -28.14% |
| 2004 Q4 | 782.92 Thousand USD | -9.21% |
| 2004 Q3 | 862.33 Thousand USD | 23.5% |
| 2004 Q2 | 698.24 Thousand USD | -29.96% |
| 2004 FY | 3.34 Million USD | 2.33% |
| 2003 Q1 | 1.11 Million USD | -22.07% |
| 2003 FY | 3.26 Million USD | -65.25% |
| 2003 Q3 | 782.16 Thousand USD | 3872.79% |
| 2003 Q4 | 1.38 Million USD | 77.37% |
| 2003 Q2 | 19.68 Thousand USD | -98.23% |
| 2002 Q4 | 1.43 Million USD | -46.54% |
| 2002 FY | 9.39 Million USD | -40.37% |
| 2002 Q1 | 2.63 Million USD | -58.16% |
| 2002 Q3 | 2.67 Million USD | 0.99% |
| 2002 Q2 | 2.64 Million USD | 0.34% |
| 2001 Q4 | 6.3 Million USD | 99.76% |
| 2001 Q3 | 3.15 Million USD | 18.02% |
| 2001 Q2 | 2.67 Million USD | -25.85% |
| 2001 FY | 15.75 Million USD | 26.01% |
| 2001 Q1 | 3.6 Million USD | 25.61% |
| 2000 Q3 | 4.06 Million USD | 34.9% |
| 2000 Q4 | 2.87 Million USD | -29.33% |
| 2000 FY | 12.5 Million USD | 76.1% |
| 2000 Q2 | 3.01 Million USD | 18.29% |
| 2000 Q1 | 2.54 Million USD | 112.36% |
| 1999 Q2 | 2 Million USD | 17.65% |
| 1999 Q3 | 2.1 Million USD | 5.0% |
| 1999 Q1 | 1.7 Million USD | 6.25% |
| 1999 Q4 | 1.2 Million USD | -42.86% |
| 1999 FY | 7.1 Million USD | 10.94% |
| 1998 Q1 | 1.6 Million USD | 14.29% |
| 1998 FY | 6.4 Million USD | 28.0% |
| 1998 Q4 | 1.6 Million USD | 6.67% |
| 1998 Q3 | 1.5 Million USD | -11.76% |
| 1998 Q2 | 1.7 Million USD | 6.25% |
| 1997 Q2 | 1.3 Million USD | 18.18% |
| 1997 Q3 | 1 Million USD | -23.08% |
| 1997 FY | 5 Million USD | 163.16% |
| 1997 Q4 | 1.4 Million USD | 40.0% |
| 1997 Q1 | 1.1 Million USD | 0.0% |
| 1996 FY | 1.9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 601.178% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 232.677% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 137.501% |
| Nascent Biotech, Inc. | -2.22 Million USD | 400.145% |
| Rebus Holdings, Inc. | -664 Thousand USD | 1107.964% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 91.823% |
| Qrons Inc. | -643.67 Thousand USD | 1139.789% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 1818.017% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 112.058% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1710.883% |
| Skye Bioscience, Inc. | -13.67 Million USD | 148.954% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 109.323% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -36.178% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 2657.209% |
| SQZ Biotechnologies Company | -75.82 Million USD | 108.827% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 334.796% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 535.72% |
| Mesoblast Limited | -84.14 Million USD | 107.954% |
| Marizyme, Inc. | -34.08 Million USD | 119.635% |
| Genus plc | 6.4 Million USD | -4.576% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 31.302% |
| Pharming Group N.V. | -4.87 Million USD | 237.162% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 436.922% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 818.598% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 180.154% |
| ContraFect Corporation | -56.88 Million USD | 111.765% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 246.944% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 577.384% |
| IMV Inc. | -38.67 Million USD | 117.307% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 343.303% |
| MultiCell Technologies, Inc. | -722.81 USD | 926052.878% |
| ONE Bio Corp. | 13.68 Million USD | 51.081% |
| Accustem Sciences Inc. | -3.74 Million USD | 278.647% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 111.346% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 1485.512% |
| Q BioMed Inc. | -3.44 Million USD | 294.243% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -89.064% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 354.722% |
| Biomind Labs Inc. | -1 Million USD | 762.922% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 112.175% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 330.69% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 200.675% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 458.989% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 22445.353% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 142.174% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 446.313% |
| GB Sciences, Inc. | -1.42 Million USD | 571.161% |
| Alpha Cognition Inc. | -9.7 Million USD | 168.959% |
| HST Global, Inc. | -140.9 Thousand USD | 4849.856% |
| CSL Limited | 3.7 Billion USD | 99.819% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 694.972% |
| Halberd Corporation | -75.05 Thousand USD | 9017.895% |
| Enzolytics Inc. | -2.14 Million USD | 411.471% |
| Agentix Corp. | -1.37 Million USD | 587.906% |
| Resverlogix Corp. | -12.74 Million USD | 152.497% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 311.247% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 101.575% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 741.08% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 329.252% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 523.773% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 296.562% |
| Zenith Capital Corp. | -8.94 Million USD | 174.839% |
| Genscript Biotech Corporation | -415.79 Million USD | 101.61% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 38518.46% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 372.587% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 4002.337% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 433.85% |
| Kadimastem Ltd | -3.04 Million USD | 320.142% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 780.134% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 632.873% |
| BioStem Technologies, Inc. | -7.77 Million USD | 186.038% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 3787.842% |
| LadRx Corporation | -3.82 Million USD | 275.04% |
| Cell Source, Inc. | -4.32 Million USD | 254.736% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1074.289% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1074.289% |
| NovAccess Global Inc. | -2.46 Million USD | 371.323% |
| Affymax, Inc. | -15.04 Million USD | 144.483% |
| Itoco Inc. | -919.14 Thousand USD | 828.168% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 257.91% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 698.113% |
| Mobile Lads Corp. | -554.55 Thousand USD | 1306.903% |
| CytoDyn Inc. | -18.05 Million USD | 137.063% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 26690.703% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 3141.14% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 1285.162% |
| SYBLEU INC | -149.18 Thousand USD | 4586.446% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 468.486% |
| International Stem Cell Corporation | -663 Thousand USD | 1109.484% |
| Bioxytran, Inc. | -3.82 Million USD | 275.2% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 12814.438% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 33005.015% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 118.455% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 513.651% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 1009.563% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 315.136% |
| Neutra Corp. | -229.48 Thousand USD | 3016.465% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 138.16% |
| PureTech Health plc | -146.19 Million USD | 104.578% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 131.143% |
| IXICO plc | -1.43 Million USD | 565.754% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 170.518% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 105.495% |
| CSL Limited | 3.81 Billion USD | 99.824% |
| Cellectis S.A. | -108.85 Million USD | 106.148% |